SBFM

+ Watchlist + Portfolio

Sunshine Biopharma Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.17
52-Week Range: $1.03 – $24.30
Market Cap: $4.50M
P/E (TTM): —
EPS (TTM): -9.08
Dividend Yield: —

Advanced Metrics

Price/Book: 0.03
PEG Ratio: —
Return on Equity: -21.92%
Return on Assets: -9.91%
Gross Margin: 30.30%
Operating Margin: -17.41%
Profit Margin: -16.50%
Current Ratio: 5.46
Debt/Equity: 0.02
Total Debt: $678.34K
Free Cash Flow: $-2.01M
Revenue Growth: -1.60%
Earnings Growth: —
Enterprise Value: $-8.80M

SBFM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$4.35M	$24.09M	$34.87M	$36.31M
Cost of Revenue	$2.65M	$15.75M	$24.20M	$24.05M
Gross Profit	$1.70M	$8.34M	$10.67M	$12.26M
Research & Development	$811.86K	$1.86M	$933.90K	$604.31K
Selling, General & Admin	$9.48M	$10.83M	$14.94M	$15.33M
Operating Expenses	$10.37M	$13.12M	$16.48M	$16.73M
Operating Income	-$8.67M	-$4.79M	-$5.81M	-$4.48M
EBITDA	-$26.45M	-$3.82M	-$5.14M	-$5.62M
Pretax Income	-$26.51M	-$4.11M	-$5.37M	-$5.95M
Income Tax	$233.30K	$395.17K	-$234.86K	$21.61K
Net Income	-$26.74M	-$4.51M	-$5.13M	-$5.98M
Diluted EPS	-23688.61	-3513.60	-73.20	-14.40
Diluted Shares	1129	1282	70174	415708

SBFM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$21.83M	$16.29M	$9.69M	$9.12M
Receivables	$1.91M	$2.55M	$3.87M	$3.46M
Inventory	$3.29M	$5.73M	$11.28M	$13.47M
Current Assets	$27.31M	$24.89M	$25.97M	$26.85M
Total Assets	$29.24M	$27.35M	$30.56M	$30.08M
Current Liabilities	$6.93M	$5.55M	$6.31M	$6.44M
Total Debt	$765.26K	$657.71K	$952.48K	$812.42K
Total Liabilities	$7.62M	$6.14M	$7.06M	$7.04M
Retained Earnings	-$59.40M	-$63.91M	-$69.04M	-$75.02M
Shareholders' Equity	$21.63M	$21.21M	$23.50M	$23.04M
Working Capital	$20.38M	$19.34M	$19.65M	$20.41M

SBFM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.25M	-$8.78M	-$12.52M	-$5.33M
Capital Expenditure	-$305.00K	-$788.10K	-$1.98M	-$836.31K
Free Cash Flow	-$5.55M	-$9.56M	-$14.50M	-$6.17M
Depreciation & Amortisation	$25.16K	$149.15K	$223.53K	$332.07K
Investing Cash Flow	-$14.62M	-$656.15K	-$1.98M	-$836.31K
Financing Cash Flow	$39.47M	$3.43M	$8.94M	$4.75M
Share Repurchases	-$99.00K	-$541.14K	-$3.14M	$0.00
Net Change in Cash	$19.60M	-$6.01M	-$5.56M	-$1.42M

SBFM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$8.90M	$9.41M	$9.42M	$8.58M	$8.09M
Cost of Revenue	$6.17M	$5.99M	$6.34M	$5.55M	$5.91M
Gross Profit	$2.73M	$3.42M	$3.07M	$3.03M	$2.18M
Research & Development	$215.28K	$196.23K	$119.30K	$73.50K	$31.72K
Selling, General & Admin	$3.64M	$4.03M	$3.27M	$4.39M	$3.34M
Operating Expenses	$4.03M	$4.42M	$3.61M	$4.69M	$3.58M
Operating Income	-$1.30M	-$992.85K	-$531.96K	-$1.66M	-$1.40M
EBITDA	-$1.23M	-$1.91M	-$925.10K	-$1.63M	-$1.32M
Pretax Income	-$1.22M	-$1.98M	-$1.02M	-$1.73M	-$1.24M
Income Tax	-$40.16K	-$209.17K	-$137.44K	$408.37K	$0.00
Net Income	-$1.18M	-$1.77M	-$883.82K	-$2.14M	-$1.24M
Diluted EPS	-4.40	-3.90	-1.90	—	-2.50
Diluted Shares	270329	449610	455594	—	490594

SBFM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$8.12M	$10.31M	$9.31M	$9.12M	$6.91M
Receivables	$3.45M	$3.59M	$4.16M	$3.46M	$4.01M
Inventory	$11.86M	$13.02M	$14.06M	$13.47M	$13.17M
Current Assets	$24.48M	$27.85M	$27.97M	$26.85M	$24.78M
Total Assets	$29.19M	$31.97M	$31.49M	$30.08M	$27.93M
Current Liabilities	$5.76M	$5.57M	$6.65M	$6.44M	$5.88M
Total Debt	$936.18K	$929.03K	$854.76K	$812.42K	$744.84K
Total Liabilities	$6.48M	$6.28M	$7.29M	$7.04M	$6.41M
Retained Earnings	-$70.22M	-$71.99M	-$72.87M	-$75.02M	-$76.26M
Shareholders' Equity	$22.70M	$25.68M	$24.20M	$23.04M	$21.52M
Working Capital	$18.72M	$22.28M	$21.32M	$20.41M	$18.91M

SBFM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.70M	-$1.29M	-$727.80K	-$1.62M	-$2.07M
Capital Expenditure	-$212.02K	-$550.19K	-$34.14K	-$39.96K	-$104.52K
Free Cash Flow	-$1.91M	-$1.84M	-$761.94K	-$1.66M	-$2.18M
Depreciation & Amortisation	$64.79K	$72.53K	$96.16K	$98.58K	$76.86K
Investing Cash Flow	-$212.02K	-$455.79K	-$118.30K	-$50.21K	-$104.52K
Financing Cash Flow	$355.30K	$3.59M	$75.54K	$724.50K	$0.00
Share Repurchases	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	-$1.55M	$1.85M	-$770.56K	-$941.72K	-$2.18M

Market Snapshot

About

Sunshine Biopharma Inc. is a pharmaceutical company developing treatments for cancer and other diseases. The company is advancing multiple drug candidates including anticancer compounds and coronavirus therapeutics through preclinical and clinical stages. Sunshine Biopharma focuses on innovative small molecule drugs targeting unmet medical needs.